| Bioactivity | SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent inhibitory activity for SARS-CoV-2 3CLpro with an IC50 value of 4.9 μM. SARS-CoV-2 3CLpro-IN-6 can be used for the research of coronavirus disease 2019 (COVID-19)[1]. |
| Target | IC50: 4.9 μM (SARS-CoV-2 3CLpro) |
| Invitro | SARS-CoV-2 3CLpro-IN-6 (Compound 13) (0-100 μM) has potent inhibitory activity for SARS-CoV-2 3CLpro with IC50 value of 4.9 μM[1].SARS-CoV-2 3CLpro-IN-6 (5, 10 μM) has typical covalent inhibition behavior with time-dependent activity[1]. |
| Name | SARS-CoV-2 3CLpro-IN-6 |
| CAS | 302821-53-0 |
| Formula | C22H15NO7 |
| Molar Mass | 405.36 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Liying Wang, et al. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. Eur J Med Chem. 2022 Dec 15;244:114803. |
SARS-CoV-2 3CLpro-IN-6
CAS: 302821-53-0 F: C22H15NO7 W: 405.36
SARS-CoV-2 3CLpro-IN-6 is a reversible covalent inhibitor of SARS-CoV-2 3CL protease. SARS-CoV-2 3CLpro-IN-6 has potent
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.